Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

Meg J JardineZien ZhouKenneth W MahaffeyMegumi OshimaRajiv AgarwalGeorge L Bakris Harpreet S BajajScott BullChristopher P CannonDavid M CharytanDick de ZeeuwGian Luca Di TannaTom GreeneHiddo J L HeerspinkAdeera LevinBruce NealCarol PollockRose QiuTao SunDavid C WheelerHong ZhangBernard ZinmanNorman RosenthalVlado Perkovicnull null

Published in: Journal of the American Society of Nephrology : JASN (2020)

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791.

Keyphrases

diabetic nephropathy
metabolic syndrome
adipose tissue
skeletal muscle
insulin resistance
weight loss